Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 488

• Price / Volume Information    Yesterday's Closing Price: $40.67 Daily Weekly Monthly 20 Day Moving Average: 572,276 shares Shares Outstanding: 58.31 (millions) Market Capitalization: $2,371.62 (millions) Beta: 0.89 52 Week High: $62.58 52 Week Low: $23.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.15% -2.48% 12 Week 9.89% 5.33% Year To Date 23.77% 8.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - ir@agios.com http://www.agios.com

• General Corporate Information    Officers Brian Goff - ChiefExecutiveOfficer Jacqualyn A. Fouse - Chair of the Board of Directors Cecilia Jones - Chief Financial Officer T.J. Washburn - Vice President; Controller Rahul Ballal - Director Peer Information Agios Pharmaceuticals, Inc. (CORR.) Agios Pharmaceuticals, Inc. (RSPI) Agios Pharmaceuticals, Inc. (CGXP) Agios Pharmaceuticals, Inc. (BGEN) Agios Pharmaceuticals, Inc. (GTBP) Agios Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/12/26 Share - Related Items Shares Outstanding: 58.31 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $2,371.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.96 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 6.71% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.85 Price/Cash Flow: - Price / Sales: 52.95 EPS Growth vs. Year Ago Period: -142.38% vs. Previous Quarter: 7.77% Sales Growth vs. Year Ago Period: 43.69% vs. Previous Quarter: 3.41% ROE 09/30/25 - -28.35 06/30/25 - -3.49 03/31/25 - -2.75 ROA 09/30/25 - -26.42 06/30/25 - -3.23 03/31/25 - -2.52 Current Ratio 09/30/25 - 13.82 06/30/25 - 14.48 03/31/25 - 18.50 Quick Ratio 09/30/25 - 13.39 06/30/25 - 14.04 03/31/25 - 17.93 Operating Margin 09/30/25 - -895.86 06/30/25 - -128.03 03/31/25 - -98.37 Net Margin 09/30/25 - -895.86 06/30/25 - 1,590.42 03/31/25 - 1,798.26 Pre-Tax Margin 09/30/25 - -915.68 06/30/25 - 1,698.66 03/31/25 - 1,917.72 Book Value 09/30/25 - 22.02 06/30/25 - 23.57 03/31/25 - 25.32 Inventory Turnover 09/30/25 - 0.19 06/30/25 - 0.17 03/31/25 - 0.17 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©